Geographic Atrophy

• EMA withdrawal · 2025-10-30
  EMA Refused: Syfovre — Apellis Europe B.V.

  The EMA refused to grant marketing authorization for Syfovre (pegcetacoplan) for geographic atrophy associated with age-related macular dege…

• EMA withdrawal · 2025-02-04
  EMA Application withdrawn: Izelvay (avacincaptad pegol) — Astellas Pharma Europe B.V.

  EMA has withdrawn the marketing authorization application for Izelvay (avacincaptad pegol) submitted by Astellas Pharma Europe B.V. for geog…

• CLINICAL_TRIALS withdrawal · 2025-02-03
  Clinical Trial Update: Efficacy and Safety Study of CNTO 2476 in Participants With Visual Acuity Impairment Associated With Geographic Atrophy (GA) Secondary to Age Related Macular Degeneration (AMD) [Phase 2]

  Phase 2 trial evaluating CNTO 2476 for visual acuity impairment due to geographic atrophy from age-related macular degeneration has been wit…